When entering the Title of your abstract, keep in mind that the abstract is limited to a total of 2,140 characters (not including spaces), INCLUDING the abstract title.

Author information does not count towards the character limit.

The authors included should be those who contribute significantly to the intellectual content of the case report (maximum 50 authors). When adding authors to your abstract, the Full Name, Affiliation, Email Address, and professional specialty of each author must be included. You will be able to use the ISHLT database search tool on the submission site to search and add your authors. Authors will be listed in the author block in the order they are added but can be rearranged after adding,

The Submitting Author is responsible for notifying all named co-authors that they will be listed as a co-author on a submitted abstract.

The Presenting Author will be the only author to receive notification of acceptance/rejection of a submitted abstract; therefore, it is the Presenting Author's responsibility to notify all co-authors regarding the outcome of an abstract submission. If the abstract is accepted for presentation at the ISHLT2023 Annual Meeting, the Presenting Author must register to attend the meeting in person. If a change in Presenting Author must be made after the submission deadline, the Presenting Author will be given the opportunity to do so in January 2023.

ONLY individuals whose formal professional training was completed five or fewer years ago, including Trainees and Students, are eligible to submit case reports. The submitter will be asked to confirm that the Presenting Author is either a Student or Trainee, Resident, Fellow, or Early Career (5 or less years).

Your case report may be submitted into only one of the below categories. Submission of the same case report into multiple categories is not permitted. Submission of one study as several different case reports is not permitted. If the case reports in question are not different enough to be considered separate studies, or if the same case report is submitted into multiple categories, all versions may be rejected.

Case Report Submission Categories are separated into four Core Therapies:

• ►  HEART (Advanced Heart Failure and Transplantation)
• ►  LUNG (Advanced Lung Failure and Transplantation)
• ►  MCS (Mechanical Circulatory Support)
• ►  PVD (Pulmonary Vascular Disease (PAH and CTEPH)

CASE REPORT SUBMISSION CATEGORIES:

	Advanced Heart Failure and Transplantation
■  COVID-19 ■  Donor Related/Early Complications Post-Transplant ■  Heart Failure/Cardiogenic Shock (non-device related) ■  Infectious Diseases ■  Long Term Follow-up Post Transplant ■  Multidisciplinary Clinical Conundrums ■  Pediatrics ■  Rejection ■  Surgical ■  Other
	Advanced Lung Failure and Transplantation
■  COVID-19 ■  Donor/Surgical/Anesthesia Considerations ■  Drug Induced Complications ■  Immunology/Rejection ■  Non-Covid Infectious Disease ■  Novel/Rare Indications for Transplant ■  Patient-Centered Management (Bedside, Peri-operative, Rehabilitation) ■  Post-Transplant Complications (Other, Non-Infectious Non-Immune) ■  Other
	Mechanical Circulatory Support
■  Anticoagulation/Thrombosis/Bleeding ■  Cardiac Complications ■  Infectious Complications ■  Myocardial Recovery/Hemodynamics ■  Nursing/Allied Health ■  Pediatrics/Congenital Heart Disease ■  Surgical Approaches ■  Temporary Circulatory Support ■  Other
	Pulmonary Vascular Disease
■  CTED/CTEPH ■  Interventions in PH ■  PAH ■  Right Heart Failure ■  Other

You will be asked to select the Primary Practice Area most relevant to your case report, as well as any additional practice areas applicable.

• ►  Anesthesiology & Critical Care
• ►  Cardiology
• ►  Cardiothoracic Surgery
• ►  Infectious Diseases
• ►  Nursing and Allied Health
• ►  Pathology
• ►  Pediatrics
• ►  Pharmacy and Pharmacology
• ►  Pulmonology
• ►  Research and Immunology

During abstract submission, the following questions will be asked:

* Is the presenting author an employee or owner of an ineligible company? (Yes/No)
REMINDER: An ACCME-defined ineligible company is an entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

* Are any co-authors listed on the abstract an employee or owner of an ineligible company? (Yes/No)
If yes, enter the co-author name(s), separated by semicolons, in the space provided.

* Is this abstract being funding (in part or in whole) by industry? (Yes/No)
If yes, enter the name of the company in the space provided. If more than one company, enter company names separated by semicolons.

In this step, the abstract body (introduction, case report, and summary) and any tables or images are entered. Case Report submission content should include:

• ►  Introduction
• ►  Case Report
• ►  Summary

SIZE LIMIT

• ►  2,140 characters (spaces are ignored)
• ►  Includes characters in the Abstract Title, Abstract Body, Table(s), and Image(s).
• ►  Includes characters in the default headings Introduction, Case Report,/strong> and Summary.
• ►  A Table/Image removes 320 characters from your character limit.
• ►  Author names and institutions are not counted in the character limit.

REMINDERS

• ►  Proofread abstracts carefully to avoid errors before submission.
• ►  You may return to your abstract to make corrections to any portion of the abstract submission, including authors, up until the submission deadline.
• ►  Corrections are not permitted after the submission deadline.

A $25 (USD) processing fee must accompany each abstract. ISHLT accepts payment only in the form of MasterCard, Visa and American Express. Purchase orders, checks, and electronic bank transfers will not be accepted. This fee is non-refundable and used to cover the cost of submission and processing.

A disclosure statement must be collected from the Submitting Author. If the abstract is accepted, a disclosure will be collected from the Presenting Author (if different from the Submitting Author).

If all submission steps are completed, the submission is marked COMPLETE and no further action is required but abstracts can still be edited by the submitter until the deadline.

If one or more submission steps are not completed, the system will indicate which steps must be finished before the submission is marked COMPLETE.